IQVIA_Rules_Based_Medicine_Logo - rgb

(+01) 512 835 8026

Email us

Type your search term and press "enter."

Quanterix Simoa-based services

Our Platforms

Rules-Based Medicine (RBM) brings more than 20 years of expertise in internally developing, manufacturing, and validating multiplex immunoassays. We offer testing on three industry-leading platforms: Luminex® xMAP® multi-analyte platform, Quanterix® Simoa® single-molecule array platform, and the Olink® multiplex platform.

 

Luminex MAP-based assays

RBM began by developing assays validated to clinical laboratory standards for the Luminex® xMAP® platform. This bead-based platform enables RBM to simultaneously detect and quantify 200+ targets in a single sample. Our menu of quantitative, multiplex assays is one of the most comprehensive menus available. We have also developed and validated our own approach using multiplex, MAP-based profiles for various therapeutic areas. Our profiles combine assays for optimized multiplexes, delivering maximum data per sample volume.

Learn more about our Luminex-based services

 

Quanterix Simoa-based assays

In 2014, we began building our own ultrasensitive immunoassays on the Simoa platform to quantify protein biomarkers previously impossible to measure. This platform can measure individual proteins at concentrations up to 1000 times lower than the immunoassays available at that time. The Single Molecule Array (Simoa) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, providing new applications to address unmet needs in life sciences research. RBM offers ~50 in-house developed Simoa assays and is regularly adding new markers to support unmet needs in therapeutic development.

Learn more about our Simoa-based services

 

Olink

In 2024, RBM added Olink to its service offering. Olink’s proximity extension assay (PEA) technology delivers optimal specificity with the scalability of high-throughput, multiplex protein biomarker analysis. The Target 48 panels enable quantitative measurement of 45 immune-related proteins from a low sample volume.

Learn more about our Olink services

 

RBM combines precision science with the dependability of automated liquid handling systems, advanced quality monitoring, validated data reporting processes, and our dedicated team of experienced scientists, project managers, and lab technicians.